Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

essential pharmaceuticals ltd - amylase; protease; lipase - gastro-resistant granules - 4000unit ; 300unit ; 5000unit

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

essential pharmaceuticals ltd - amylase; lipase; protease - gastro-resistant tablet - 5000unit ; 5600unit ; 330unit

Israel - Inggris - Ministry of Health

mbi pharma ltd., israel - dexamethasone as sodium phosphate - solution for injection - dexamethasone as sodium phosphate 4 mg/ml - dexamethasone - dexamethasone kern pharma is indicated in the treatment of:• endocrine diseases such as nonsuppurative thyroiditis, hypercalcaemia associated with cancer and congenital adrenal hyperplasia.• allergy: severe or disabling allergic conditions resistant to conventional treatments, as in: bronchial asthma, contact or atopical dermatitis, seasonal or perennial allergic rhinitis, hypersensitivity reactions to drugs.• ophtalmic: serious inflammatory and allergic processes, acute and chronic, affecting the eyes, such as: iritis and iridocyclitis, chorioretinitis, choroiditis and diffuse posterior uveitis, optical neuritis, allergic conjunctivitis, allergic marginal corneal ulcers.• inflammatory bowel dis.: systemic treatment in exacerbations of ulcerative colitis and regional enteritis.• dermatological diseases (pemphigus, stevens johnson syndrome, exfoliative dermatitis, severe psoriasis and mycosis fungoides) • respiratory diseases (symptomatic sarcoidosis, berylliosis, loeffler's syndrome)• haematologica

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

essential pharma ltd - amylase; lipase; protease - oral capsule - 3300unit ; 2950unit ; 160unit

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

essential pharma ltd - amylase; lipase; protease - oral capsule - 9000unit ; 8000unit ; 430unit

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

essential pharma ltd - carbamazepine - suppository - 125mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

essential pharma ltd - carbamazepine - suppository - 250mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

essential pharmaceuticals ltd - ascorbic acid; riboflavin; thiamine hydrochloride; pyridoxine hydrochloride; nicotinamide; calcium pantothenate; alpha tocopheryl acetate; inositol; biotin; folic acid; acetomenaphthone - oral tablet - 16.6mg ; 1mg ; 1mg ; 330microgram ; 3.3mg ; 1.16mg ; 5mg ; 50mg ; 170microgram ; 250microgram ; 500microgram

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

essential-healthcare ltd. - acetylcystein - effervescent tablet - 600 milligram(s) - mucolytics; acetylcysteine

Israel - Inggris - Ministry of Health

ofek pharma ltd, israel - posaconazole - tablets delayed release - posaconazole 100 mg - posaconazole - treatment of the following fungal infections in adults:- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b.- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patient intolerant to itraconazole.- coccidioidomycosis in patients with disease refractory to amphotericin b, itraconazole or fludonazole or in patient intolerant to these medicinal products.- zygomycosis in patients intolerant of or with disease that is refractory to alternative therapy.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.these are also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukemia (aml) or myelodysplatic syndrome (mds) expected to result in prolonged neutropenia who are at high-risk of developing invasive fungal infections.-hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high-risk of developing invasive fungal infections.